+357 96 030922
info@marketpublishers.com

# Veterinary Monoclonal Antibodies Market by Animal Type (Canine, Feline, Swine), Product (Cytopoint, Librela, Solensia), Therapy Area (Dermatology, Infectious, Osteoarthritis, Pain, Oncology, Others), Route of Administration - Global Forecast to 2030

https://marketpublishers.com/r/VC73463A74C0EN.html
Date: September 2025
Pages: 254
Price: US$ 4,950.00 (Single User License)
ID: VC73463A74C0EN

## Abstracts

The global veterinary monoclonal antibodies market is projected to reach USD 3.06 billion by 2030, from USD 1.70 billion in 2025, with a CAGR of 12.4%. The market is experiencing significant growth, driven by the expanding companion animal population and rising pet ownership. Growing concerns about chronic diseases have further boosted the demand for veterinary treatments. Government and animal welfare organizations actively promote awareness campaigns, encouraging early diagnosis and treatment of dermatological conditions in both pets and farm animals. However, the market faces challenges such as rising pet care costs, which can limit treatment adoption. Furthermore, strict regulatory guidelines and lengthy approval times for drugs further restrain market growth. Despite these hurdles, expanding therapeutic indications beyond dermatology and osteoarthritis continues to create new market opportunities.

“By animal type, the canine segment held the highest share in 2024.”

The canine segment held the largest market share in 2024, driven by rising pet dog ownership and increasing spending on animal healthcare. Dogs are highly prone to skin conditions such as allergies, fungal infections, and ectoparasitic infestations, which require frequent dermatological treatments. The growing trend of pet humanization and the demand for premium veterinary care further support market growth. Additionally, advancements in dermatological treatments, including biologics and targeted monoclonal antibody therapies, improve treatment outcomes for dogs, solidifying the segment’s dominance in the market.

+357 96 030922
info@marketpublishers.com

“By route of administration, the subcutaneous segment is projected to record the highest CAGR between 2025 and 2030.”

The subcutaneous segment is expected to grow at the fastest rate during the forecast period due to its ease of administration and better pet owner compliance. Rising veterinary recommendations for systemic treatments over topical solutions and the ongoing development of new monoclonal antibodies targeting infectious diseases are increasing demand. Moreover, innovations in monoclonal antibodies targeting infectious diseases further support the segment’s growth in the veterinary monoclonal antibodies market.

“By product, cytopoint was the leading segment in 2024.”

The cytopoint segment held the largest market share in 2024, driven by its status as the first and only FDA- and EMA-approved monoclonal antibody therapy for treating canine atopic dermatitis. Additionally, the high prevalence of atopic dermatitis in dogs has increased demand for cytopoint due to its proven efficacy, safety profile, and rising adoption by veterinarians. The growing willingness of pet owners to invest in advanced veterinary treatments has further fueled market growth.

“By therapy type, dermatology surpassed other segments in 2024.”

The dermatology segment held the largest market share in 2024 due to the rising prevalence of chronic diseases such as atopic dermatitis in dogs. Additionally, growing awareness of advanced treatment options like Cytopoint by Zoetis (US) has gained significant traction due to its long-lasting relief and minimal side effects in treating allergic and atopic dermatitis in dogs. The willingness to spend on pet healthcare has further driven this market growth.

“By end user, veterinary hospitals/specialty centers are expected to exhibit the fastest growth during the forecast period.”

Veterinary hospitals/specialty centers are expected to grow at the fastest rate, fueled by the rise in veterinary visits and the availability of specialized pet healthcare services. These facilities offer comprehensive treatment options, including advanced diagnostics, prescription medications, and surgical procedures for various conditions. Additionally, pet insurance coverage for dermatological treatments encourages pet owners to seek veterinary care, boosting demand in this segment.

“North America accounted for the largest share in 2024.”

North America held the largest market share in 2024, supported by a well-established veterinary healthcare infrastructure and high pet ownership rates. The region has a strong presence of leading market players investing in R&D for innovative monoclonal antibody therapies. Rising awareness about pet health, along with increasing spending on veterinary care, also drives market growth. The growing demand for premium pet care products further contributes to North America’s dominance in the global veterinary monoclonal antibodies market.

A breakdown of the primary participants referred to for this report is provided below:

By Company Type: Tier 1 – 75%, Tier 2 – 15%, and Tier 3 – 10%

By Designation: C-level – 30%, D-level – 23%, and Other Designations – 47%

By Region: North America – 35%, Europe – 20%, Asia Pacific – 25%, Latin America – 13%, and Middle East & Africa – 7%

The major players operating in the veterinary monoclonal antibodies market are Zoetis Services LLC (US), Elanco (US), and Merck & Co., Inc. (US).

**Research Coverage**

This report examines the veterinary monoclonal antibodies market based on animal type, product, therapy area, route of administration, end user, and region. It also considers factors such as drivers and restraints that influence market growth. The report highlights opportunities and challenges within the market and offers details about the competitive landscape for market leaders. Additionally, it analyzes micro markets concerning their individual growth trends and forecasts the revenue of market segments across five main regions and their respective countries.

**Reasons to Buy this Report**

The report can assist both established firms and new or smaller companies in understanding the market dynamics, which can help them increase their market share. Companies purchasing the report may employ one or a combination of the five strategies listed below.

This report provides insights into the following points:

- Analysis of key drivers (increased prevalence of chronic diseases in animals, innovation in monoclonal antibodies targeting infectious diseases, rise in companion animal population and pet ownership, growth in veterinary healthcare expenditure), restraints (regulatory hurdles and long approval timelines, high cost of development and treatment), opportunities (expanding therapeutic indications beyond dermatology and osteoarthritis, novel administration routes for monoclonal antibodies, rising strategic developments among market players in development of veterinary monoclonal antibodies), and challenges (emerging safety concerns and adverse events reporting, and limited species-specific knowledge) influencing the growth of veterinary monoclonal antibodies market

- Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the veterinary monoclonal antibodies market

- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of monoclonal antibody treatments across regions.

- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the veterinary monoclonal antibodies market

- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the veterinary monoclonal antibodies market

# Contents

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

**12 COMPETITIVE LANDSCAPE**

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

## List Of Tables

**LIST OF TABLES**

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

## List Of Figures

**LIST OF FIGURES**

+357 96 030922
info@marketpublishers.com

## I would like to order

Product name: Veterinary Monoclonal Antibodies Market by Animal Type (Canine, Feline, Swine), Product (Cytopoint, Librela, Solensia), Therapy Area (Dermatology, Infectious, Osteoarthritis, Pain, Oncology, Others), Route of Administration - Global Forecast to 2030

Product link: https://marketpublishers.com/r/VC73463A74C0EN.html

Price: US$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/VC73463A74C0EN.html